Showing results (181-190 of 242) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Translational Oncology|February 22, 2023
Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinomaOmali Pitiyarachchi, Yeh Chen Lee, Hao-Wen Sim, et al.
Gynecologic Oncology|February 27, 2024
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancerFelicia Roncolato, Madeleine T King, Rachel L O'Connell, et al.
Gynecologic Oncology|July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancerOmali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer IntergroupMichael A Bookman, Mark F Brady, William P McGuire, et al.
Gynecologic Oncology|February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 studyFabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.
The Lancet. Oncology|July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trialMichael Friedlander, Val Gebski, Emma Gibbs, et al.
JAMA Network Open|November 5, 2025
PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-AnalysisStamatios Petousis, Ilker Kahramanoglu, Christian Appenzeller-Herzog, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapyAngelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
BMJ Open|April 13, 2023
Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trialSandra Hayes, Andreas Obermair, Linda Mileshkin, et al.
Pageof 25